Incidence and Risk Factors for Retinopathy of Prematurity (ROP) in Biggest Neonatal Intensive Care Unit in Itay Elbaroud City, Behera Province, Egypt

Raouf Gaber
Osama A Sorour
Amr F Sharaf
Hisham A Saad

Department of Ophthalmology, Tanta University, Tanta, Gharbeya Province, Egypt

Aim of the Work: To evaluate the incidence and risk factors for development of retinopathy of prematurity (ROP) in the biggest neonatal intensive care unit (NICU) in Itay Elbaroud City, Behera province, Egypt.

Methods: We studied data of 240 newly born infants with gestational age (GA) ≤34 weeks or birth weight (BW) ≤2000 g or infants with unstable course who were admitted to the biggest NICU in Itay Elbaroud City, Behera province, Egypt, between October 1, 2018 and October 31, 2020. There is no standard screening system in Egypt. Furthermore, we had screened babies more than 1500 g, more than 32 weeks and found signs of ROP, so we decided to expand our inclusion criteria to include babies up to 2000 g of birth weight and up to 34 weeks gestational age in addition to older and heavier babies with unstable course in NICUs. Clinical information about perinatal neonates was collected by reviewing medical charts. The main outcomes are the incidence and severity of ROP. The relationship of clinical risk factors and the development of ROP were analyzed.

Results: The overall incidence of ROP was 34.1%, and the overall incidence of type 1 ROP was 26.3% of infants. ROP was significantly associated with GA (odds ratio; OR: 6.8; (3.7–12.3), BW (OR: 4.1; 2.3–7.3), apnea, supplementary oxygen administration, and thrombocytopenia.

Conclusion: The incidence of ROP is high in Itay Elbaroud city, Behera Province, Egypt. Immaturity, low birth weight, low gestational age, oxygen administration, apnea, thrombocytopenia, and jaundice are important risk factors for development of ROP.

Keywords: birth weight, gestational age, incidence, retinopathy of prematurity

Introduction
Retinopathy of prematurity is considered a real public health problem in low and middle-income countries like Egypt, Brazil, and India; and it is considered one of the leading causes of childhood blindness worldwide.¹ Advancement in neonatal care worldwide has improved the survival rate of premature infants and meanwhile, the incidence of ROP has also increased.²,³ Few research articles evaluated the magnitude of this health problem in Egypt. There is no standard screening system in Egypt. Furthermore, we had screened babies more than 1500 g, more than 32 weeks gestational age (GA) and found signs of ROP, so, we decided to expand our inclusion criteria to include babies up to 2000 g of birth weight and up to 34 weeks GA in addition to older and heavier babies with unstable course in NICUs.

Many risk factors have been associated with developing ROP as low birth weight,⁴,⁵ low gestational age, sepsis,⁵ apnea and prolonged exposure to...
supplementary oxygen. In the current study, we evaluate the incidence, risk factors of ROP in the biggest NICU in Itay Elbaroud city, Behera province, Egypt.

Aim of the Work
The aim of this study was to evaluate the incidence of ROP at a big NICU in Itay Elbaroud city, Behera province, Egypt, along with the risk factors for this big public health problem.

Methods
This is a retrospective cross-sectional study in which we reviewed the charts of 240 infants who underwent fundus examination for both eyes for screening of ROP in the biggest NICU in Itay Elbaroud city, Behera province, Egypt between October 1, 2018 and October 31, 2020. The criteria of screening were infants with GA ≤34 weeks, birth weight (BW) ≤2000 g or infants with unstable course. Ethical Committee approval from Tanta University, Egypt was obtained. The study was conducted in accordance with the tenets of the Declaration of Helsinki and the guidelines of good clinical practice. Informed consent was signed by the parent or the legal guardian of the infant before enrollment.

Baseline characteristics of the patients, including gender, gestational age at birth, birth weight, stage of ROP at presentation, and presence of multiple pregnancies, were collected from the charts. Risk factors of ROP were evaluated including oxygen therapy during admission in NICU, apnea, sepsis, thrombocytopenia, blood transfusion, exchange transfusion and phototherapy. The main outcome measures were the incidence, severity and management of ROP. The relationship between clinical risk factors and development of ROP was analyzed.

Eye Examination Method
One retina specialist (RG) who had sufficient training and experience to diagnose and identify stages and zones of ROP performed all examinations. Pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine drops two hours before examination. Indirect ophthalmoscopy was routinely used with a pediatric lid speculum and scleral indentation under topical anesthesia. Digital retinal images were also obtained using a wide-field retinal camera (RetCam II 120, Clarity Medical System Inc., Pleasanton, CA, USA) for documentation of retinal finding.

Statistical Analysis
Data was collected and stored in a spreadsheet. Descriptive continuous variables are normally distributed, therefore; they were presented using the mean and standard deviation; whereas categorical variables were reported as proportions (percent). Statistical analysis was carried out using SPSS version 23.0 (SPSS, Inc., Chicago, IL, USA) and R software (version 3.1–122; R Foundation for Statistical Computing, Vienna, Austria). For all hypothesis tests, two-sided P-value of <0.05 was considered as statistically significant.

Results
Two hundred and forty infants met our inclusion criteria of screening; among whom 132 were males (55%), all of them are white Caucasian race. They had a mean gestational age of 33.25±2.74 weeks (range: 26–39 weeks). Mean birth weight 1955.23±692.43 g (range: 820–5500 g). Eighty-two included infants (34.1%) had ROP; including 63 infants with type 1 ROP that required therapeutic intervention. Treatment was performed in the form of intravitreal injection of an anti-VEGF drug. Ongoing surveillance for recurring ROP after anti-VEGF therapy was done by follow-up fundus examination visits even after discharging the baby from NICU until the age of 65 weeks, there was no recurring ROP after the anti-VEGF therapy.

Twenty-six multiple pregnancies were included (21 twins and 5 triplets); where 11 infants had aggressive posterior ROP, presenting with flat neovascularization at the posterior pole.

Most of the included infants in the study had stage 3 ROP (35 infants, 42.6%) (Table 1), followed by stage 2 ROP (22 infants, 26.8%), aggressive posterior ROP (11 infants, 13.4%) and stage 1 ROP (10 infants, 12%). Only one infant had stage 4 ROP (0.01%), and none of the included infants had stage 5 ROP (Table 1).

For statistical analysis, we divided the cases per birth weight into five subgroups: less than 1000 g (two infants, 0.8%), 1000–1250 g (28 infants, 11.6%), 1251–1500 g (52 infants, 21.6%), 1501–2000 g (67 infants, 28%) and more than 2000 g (91 infants, 38%) (Table 2). And the cases are divided into three groups according gestational age (Table 3) less than 28 weeks (five infants, 2%), 28–31 weeks (60 infants, 25%) and more than 31 weeks (175 infants, 72.9%).

Table 1: Incidence of ROP in different birth weight subgroups

| Birth Weight (g) | No. of Infants | Incidence |
|------------------|---------------|-----------|
| ≤1000            | 2             | 0.8%      |
| 1000–1250        | 28            | 11.6%     |
| 1251–1500        | 52            | 21.6%     |
| 1501–2000        | 67            | 28%       |
| >2000            | 91            | 38%       |

Table 2: Incidence of ROP in different gestational age subgroups

| Gestational Age (weeks) | No. of Infants | Incidence |
|-------------------------|---------------|-----------|
| <28                     | 5             | 2%        |
| 28–31                   | 60            | 25%       |
| >31                     | 175           | 72.9%     |
As regards risk factors of ROP, there was a significant correlation between LBW (≤1500 gm) (OR: 4.12, CI: 2.3–7.3), low gestational age (≤32 weeks) (OR: 6.8, CI: 3.7–12.3), and oxygen supplementation through either nasal cannula (OR: 3.95, CI 1.14–13.7), CPAP (OR: 18.9, CI: 5.7–62.7) or mechanical ventilation (OR: 13.6, CI: 5.6–33.1) (Table 4).

Apnea was also a significant risk factor for development of ROP changes (OR: 15.6, CI: 8–30.2), together with thrombocytopenia (OR: 2, CI: 0.6–6.5) and phototherapy for jaundice (OR: 2.1, CI: 1.2–3.7).

As regards risk factors of ROP, there was a significant correlation between LBW (≤1500 gm) (OR: 4.12, CI: 2.3–7.3), low gestational age (≤32 weeks) (OR: 6.8, CI: 3.7–12.3), and oxygen supplementation through either nasal cannula (OR: 3.95, CI 1.14–13.7), CPAP (OR: 18.9, CI: 5.7–62.7) or mechanical ventilation (OR: 13.6, CI: 5.6–33.1) (Table 4).

Apnea was also a significant risk factor for development of ROP changes (OR: 15.6, CI: 8–30.2), together with thrombocytopenia (OR: 2, CI: 0.6–6.5) and phototherapy for jaundice (OR: 2.1, CI: 1.2–3.7).

Table 1 Demographic and Clinical Data of Included Infants

| Parameter                  | Value                                      |
|----------------------------|--------------------------------------------|
| Number of infants          | 240                                        |
| Gender                     | Male 132 (55%)                             |
|                            | Female 108 (45%)                           |
| Gestational age            | 26–39 weeks (33.25±2.74)                   |
| Birth weight               | 820–5500 g (1955.23±692.43)                |
| Multiple pregnancies       | 26 total                                   |
|                            | 21 twins                                   |
|                            | 5 triplets                                 |
| Without ROP               | 158 infants (65.8.1%)                      |
| With ROP                  | 82 infants (34.1%)                         |
| Stage 1:                    | 10                                         |
| Stage 2:                    | 22                                         |
| Stage 3:                    | 35                                         |
| Stage 4a:                   | 1                                          |
| Stage 5:                    | 0                                          |
| APROP:                     | 11                                         |
| Pre-plus with immature vascularization: | 3  |
| ROP not requiring treatment (mild ROP) | 19 infants (7.9%) |
| Type 1 ROP                | 63 infants (26.3%)                         |
| Aggressive posterior ROP   | 11 infants (4.6%)                          |

Table 2 ROP Subgroups in Relation with BW

| BW                          | No ROP | ROP | Mild ROP | Type 1 ROP |
|-----------------------------|--------|-----|----------|------------|
| ≤1000 g (n=2)               | 1      | 1   | 0        | 1          |
| 1000–1250 g (n=28)          | 12     | 16  | 2        | 14         |
| 1251–1500 g (n=52)          | 24     | 28  | 3        | 25         |
| 1501–2000 g (n=67)          | 41     | 26  | 7        | 19         |
| >2000 g (n=91)              | 80     | 11  | 7        | 4          |

Table 3 ROP Subgroups in Relation with GA

| GA                          | No ROP | ROP | Mild ROP | Type 1 ROP |
|-----------------------------|--------|-----|----------|------------|
| <28 weeks (5)               | 3      | 2   | 0        | 2          |
| 28–31 weeks (60)            | 23     | 37  | 6        | 31         |
| ≥32 weeks (175)             | 132    | 43  | 13       | 30         |

Table 4 Risk Factors Evaluated for an Association with the Development of ROP

| Risk Factors                             | OR  | 95CI%  |
|------------------------------------------|-----|--------|
| Birth weight equal or less than 1500 g   | 4.12| 2.3–7.3|
| Gestational age equal or less than 32 weeks | 6.8 | 3.7–12.3|
| Apnea                                    | 15.6| 8.05–30.2|
| Nasal cannula                            | 3.95| 1.14–13.7|
| CPAP                                     | 18.9| 5.7–62.7|
| Mechanical ventilation                   | 13.6| 5.6–33.1|
| Sepsis                                   | 1.1 | 5.6–2.17|
| Thrombocytopenia                         | 2   | 0.6–6.5|
| Blood transfusion                        | 1.15| 0.5–2.5|
| Exchange transfusion                     | 0.9 | 0.08–10.9|
| Phototherapy                             | 2.1 | 1.2–3.7|

Abbreviations: GA, gestational age; ROP, retinopathy of prematurity.

Discussion

Retinopathy of prematurity is one of the leading causes of childhood blindness worldwide. Few published research articles demonstrate the magnitude of ROP as a real health-care problem in Africa and the Middle East, particularly in Egypt. The incidence of ROP in our study was 34%, and the incidence of type 1 ROP which required treatment was 26.3%. Treatment was performed successfully in the form of intravitreal injection of antivascular endothelial growth factor (anti-VEGF).

Our results coincide with the results of Bassiouny who reported an incidence of 34% for ROP in Oman, and Maheshwari et al who also reported an incidence of 27% in India. In 2008, Binkhathlan et al reported an
incidence of 56% for ROP in Saudi Arabia, while Al-Amro et al.\textsuperscript{11} reported an incidence of 37.4% in the neonatal intensive care unit at King Khalid University Hospital in Riyadh in 2003.

The mean gestational age for babies in our study was 33.25±2.74 weeks, which is higher than that in other studies. Goble et al.\textsuperscript{12} reported a mean gestational age of 29.1±2.1 weeks, while Shah et al.\textsuperscript{13} reported a mean gestational age of 29.7±2.2 weeks, which may indicate a higher rate of mortality among infants with lower gestational age in our country.

Gestational age equal or less than 32 weeks was a risk factor for development of ROP (OR: 6.8). We found that 57% of babies born before 32 weeks developed ROP, while only 17% of babies born after 32 weeks developed ROP.

The mean birth weight for babies in our study was 1955.23±692.43 g. Thirty-nine percent of babies between 1500 and 2000 g developed ROP, so every baby with birth weight less than 2000 g should be routinely examined by a trained ophthalmologist to exclude ROP. This is contrary to Hadi and Hamdy,\textsuperscript{14} who recommended to keep the upper limit of screening of babies for ROP at 1500 g.

In our study, birth weight ≤1500 g was a risk factor for development of ROP (OR: 4). Fifty-five percent of these babies developed ROP, while only 38.8% of babies with birth weight between 1500 and 2000 g developed ROP.

We evaluated the role of apnea, oxygen supplementation (nasal cannula, CPAP, mechanical ventilation) sepsis, thrombocytopenia, blood transfusion, exchange transfusion, and phototherapy as possible risk factors for development of ROP. There was a positive correlation between oxygen supplementation either with nasal cannula (OR: 3.95, CI: 1.14–13.7), CPAP (OR: 18.9, CI: 5.7–62.7) or mechanical ventilation (OR: 13.6, CI: 5.6–33.1) and development of ROP. Our results are in agreement with other studies which confirmed the association between the risk of ROP and the use of mechanical ventilation\textsuperscript{15} and CPAP.\textsuperscript{13}

The occurrence of thrombocytopenia (OR: 2, CI: 0.6–6.5)\textsuperscript{16} is another significant risk factor for development of ROP, in addition to neonatal apnea (OR: 15.6, CI: 8–30.2) and phototherapy for jaundice (OR: 2.1, CI: 1.2–3.7).\textsuperscript{17}

**Conclusion**

ROP is a real public health problem in Egypt. Immaturity, low birth weight, low gestational age, oxygen administration, apnea, thrombocytopenia, and jaundice are important risk factors for development of ROP. Wise use of oxygen and a strict screening program that require cooperation between neonatal specialists and trained ophthalmology subspecialist are highly encouraged to avoid the devastating complications of this serious condition that has a high incidence among neonates in Egypt.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Nuddleman E, Kilic I, Gaber R, et al. Glaucoma after lens sparing vitrectomy for advanced retinopathy of prematurity. *Ophthalmology*. 2018;125(5):671–675. doi:10.1016/j.ophtha.2017.11.009
2. Valentine PH, Jackson JC, Kalina RE, et al. Increased survival of low birth weight infants: impact on the incidence of retinopathy of prematurity. *Pediatrics*. 1989;84:442–445.
3. Gibson DL, Sheps SB, Uh SH, et al. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. *Pediatrics*. 1990;6:405–412.
4. Darlow BA, Hutchinson JL, Henderson-Smart DJ, et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand neonatal network. *Pediatrics*. 2005;115(4):990–9. doi:10.1542/peds.2004-1309
5. Dhaliwal CA, Fleck BW, Wright E, et al. Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. *Arch Dis Child Fetal Neonatal Ed*. 2009;94:F193–5.
6. Gupta VP, Dhaliwal U, Sharma R, Gupta P, Rohatgi J. Retinopathy of prematurity – risk factors. *Indian J Pediatr*. 2004;71(10):887-92. doi:10.1007/BF02830827
7. Kim T, Sohn J, Pi SY, et al. Postnatal risk factors of retinopathy of prematurity. *Paediatr Perinat Epidemiol*. 2004;18(2):130-4. doi:10.1111/j.1365-3016.2003.00545.x
8. Bassiony MR. Risk factors associated with retinopathy of prematurity: a study from Oman. *J Trop Pediatr*. 1996;42(6):355–358. doi:10.1093/tropej/42.6.355
9. Maheshwari R, Kumar H, Paul VK, Singh M, Deorari AK, Tiwari HK. Incidence of retinopathy of prematurity in a tertiary care newborn unit in New Delhi. *Nat Med J India*. 1996;9:211–214.
10. Binkhathlan AA, Almahmoud LA, Saleh MJ, Srungeri S. Retinopathy of prematurity in Saudi Arabia: incidence, risk factors, and the applicability of current screening criteria. *Br J Ophthalmo*. 2008;92(2):167–169. doi:10.1136/bjo.2007.126508
11. Al-Amro SA, Al-Khafar TM, Thabit AA, Al-Mofada SM. Retinopathy of prematurity at a university hospital in Riyadh, Saudi Arabia. *Saudi Med J*. 2003;24:720–784.
12. Goble RR, Jones HS, Fielder AR. Are we screening too many babies for retinopathy? *Eye*. 1997;11(4):509–514. doi:10.1038/eye.1997.136
13. Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. *Ann Acad Med Singapore*. 2005;34:169–178.
14. Hadi AMA, Hamdy S. Correlation between risk factors during neonatal period and appearance of retinopathy of prematurity in preterm infants in neonatal intensive care units in Alexandria, Egypt. *Clin Ophthalmo*. 2013;7:831–837. doi:10.2147/OPTH.S40136
15. Al-Amro SA, Al-Khar TM, Thabit AA, Al-Mofada SM. Risk factors for acute retinopathy of prematurity. *Compr Ther*. 2007;33(2):73–77. doi:10.1007/s12091-007-0808-5
16. Jensen AK, Ying GS, Huang J, et al. Thrombocytopenia and retinopathy of prematurity. *J AAPOS*. 2011;15(1):e3–e4.
17. Ali YF, El-Morshey S, Imam AA, et al. The role of serum apelin in retinopathy of prematurity. *Clin Ophthalmo*. 2017;11:387–392. doi:10.2147/OPTH.S127943
